Clinical Trial Research
Titan Announces That Target Enrollment Has Been Met Ahead of Schedule in Phase III Clinical Study of Probuphine(R) for Opioid Dependence
Published in Healthcare Finance, Tax and Law Weekly, December 19th, 2007
This randomized, double-blind, placebo-controlled, multi-center Phase III study will evaluate the safety and effectiveness of treatment with Probuphine in reducing opioid dependence over 24 weeks of treatment in approximately 150 patients. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Accounting
New accounting data have been reported by R. Pethig and co-authors - Accounting
Research from Tufts University yields new data on accounting - Accounting
Research in the area of accounting reported from S. Cnossen and colleagues - Accounting
Study results from M. Hayashi and colleagues in the area of accounting published - Aggression
Data from Yale University, Department of Psychology provide new insights into aggression in children - Aggression
Research reports from University of California provide new insights into aggression - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
